227 related articles for article (PubMed ID: 6407887)
1. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y; Terashima H; Morimura T; Tsuboshima M
Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
[TBL] [Abstract][Full Text] [Related]
2. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new aldose reductase inhibitor on various tissues in vitro.
Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
[TBL] [Abstract][Full Text] [Related]
4. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
[TBL] [Abstract][Full Text] [Related]
5. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
Hotta N; Kakuta H; Fukasawa H; Kimura M; Koh N; Iida M; Terashima H; Morimura T; Sakamoto N
Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
[TBL] [Abstract][Full Text] [Related]
6. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
7. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
Mayer JH; Tomlinson DR
Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
[TBL] [Abstract][Full Text] [Related]
8. Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235.
Yasuda H; Sonobe M; Yamashita M; Terada M; Hatanaka I; Huitian Z; Shigeta Y
Diabetes; 1989 Jul; 38(7):832-8. PubMed ID: 2525492
[TBL] [Abstract][Full Text] [Related]
9. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
[TBL] [Abstract][Full Text] [Related]
10. Photo-stabilization and solubilization of an aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodani ne (ONO-2235), by human serum albumin.
Kurono Y; Furukawa A; Takesue Y; Li FL; Ikeda K
Chem Pharm Bull (Tokyo); 1987 Jul; 35(7):3045-8. PubMed ID: 3119240
[No Abstract] [Full Text] [Related]
11. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
[TBL] [Abstract][Full Text] [Related]
12. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
Yue DK; Hanwell MA; Satchell PM; Turtle JR
Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
[TBL] [Abstract][Full Text] [Related]
13. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
[TBL] [Abstract][Full Text] [Related]
14. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
Stribling D; Mirrlees DJ; Harrison HE; Earl DC
Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
[TBL] [Abstract][Full Text] [Related]
15. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
Cameron NE; Cotter MA; Robertson S
Q J Exp Physiol; 1989 Nov; 74(6):917-26. PubMed ID: 2512591
[TBL] [Abstract][Full Text] [Related]
16. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
[TBL] [Abstract][Full Text] [Related]
17. Effect of aldose reductase inhibition on nerve conduction velocity and resistance to ischemic conduction block in experimental diabetes.
Price DE; Airey CM; Alani SM; Wales JK
Diabetes; 1988 Jul; 37(7):969-73. PubMed ID: 3133261
[TBL] [Abstract][Full Text] [Related]
18. Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics.
Kuriya N; Miyake S; Yokota A; Yamaguchi Y; Nakanishi T; Takahashi A; Ueda Y; Mori T; Akiguchi I; Toyama K
J Med Assoc Thai; 1987 Mar; 70 Suppl 2():168-72. PubMed ID: 3110345
[No Abstract] [Full Text] [Related]
19. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
Gillon KR; Hawthorne JN; Tomlinson DR
Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
[TBL] [Abstract][Full Text] [Related]
20. Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats.
Nishikawa M; Yoshida K; Okamoto M; Itoh Y; Kohsaka M
J Antibiot (Tokyo); 1991 Apr; 44(4):441-4. PubMed ID: 1903376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
